Category Archives: Strategy

Marketing: Harnessing the Power of 'Pull'

By Guest Blogger | Published: April 3, 2013
Pull marketing – rethinking channel building A big problem Since the early days of the internet, we’ve been busy creating websites and other digital channels. It’s not an exaggeration to say that most pharmaceutical companies already have hundreds of websites and still more are coming. And now everybody is building apps. There’s a lot of activity here and in many ways [...]
Also posted in Europe, Global, Guest Blog, Marketing | Tagged , , , | Leave a comment

For Becton Dickinson, Medication Errors are a Business Opportunity

By Ben Comer | Published: April 1, 2013
Over the next few years, med tech company Becton Dickinson will launch up to 30 generic, pre-filled syringes in an attempt to lower medication errors and raise company revenues, according to BD Rx president Mark Sebree. One man’s goof is another man’s growth, potentially.
Also posted in FDA, Manufacturing, R&D, Safety, Technology, pricing | Tagged , , , , , | Leave a comment

FTC v. Actavis: The Wrong End of the Telescope

By Guest Blogger | Published: March 25, 2013
by Traci Medford-Rosow and Peter C. Richardson On December 8, 2012, the Supreme Court agreed to hear the Federal Trade Commission (FTC) v. Actavis, Inc. case. The court’s grant of certiorari marked the latest chapter in a decade-long effort by the FTC to have the court rule on the festering issue of whether pay-for-delay provisions in [...]
Also posted in IP, Legal, Market Access, Op-Ed, Regulatory | Tagged , | 1 Comment

AstraZeneca's R&D Trimdown, Points to Shift in The Way Big Pharma Invents

By Clark Herman | Published: March 20, 2013
AstraZeneca’s decision to cut 5,050 jobs by 2016 and cease R&D operations at its Alderley Park, UK facility has many wondering where CEO Pascal Soriot plans to take the company. The opening of a new $500 million facility in Cambridge is at once a consolation prize for the UK government’s efforts to placate a skittish [...]
Also posted in Biotech, Europe, R&D | Tagged , , | Leave a comment

Are US and Canadian Rx Policies Converging?

By Guest Blogger | Published: March 19, 2013
by Tom Norton As the US pharmaceutical industry anxiously watches the rapid onset of Obamacare, certainly one of the more pressing issues is the debate over the number of drugs that will be reimbursed in each therapeutic class under the Essential Health Benefits (EHB) program.  To say that this is a critical concern for the future [...]
Also posted in Global, Guest Blog, Legal, Market Access, healthcare | Tagged , , , , , , | Leave a comment